An interventional study of Implementation of echocardiography in nursing homes in Heart Diseases, Heart Failure and Heart Valve Diseases, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Heart Diseases with a site in France — 29 open to participants now, 37 under way, 5 of them phase 3. Heart Diseases · France.
Among the 126 studies in Heart Diseases with a site in France, this one is the 21st largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2024, is one of 48 with no phase, reaches primary completion later than 25 of the 36 other live ones, and was the 112th registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →29 of the 126 studies in Heart Diseases with a site in France are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in France, United States, Brazil and 6 more countries
Ages 6+
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
Kiniksa Pharmaceuticals International, plc · Sites in France, United States, Canada and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in France, Argentina, Australia and 35 more countries
Ages 50+
Lexeo Therapeutics · Sites in France, United States, Brazil and 5 more countries
Ages 6+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 22 · Phase 4 3
First in 2002; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,050 is above the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 240 across the 79 interventional studies, 375 across the 46 observational. Of the 76 that completed or were terminated, 23 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 126 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 2 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Heart Diseases with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT06420960L'hôpital Nord-Ouest - Villefranche Villefranche sur SaôneDiagnostic Efficacy of Connected WAtch ECG Versus External Holter ECG | 2027-01-18 |
| NCT07888218Central Hospital, Nancy, FranceReplacing Spatial Filtering With Deep-learning Noise Reduction | 2027-01-23 |
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 126 studies in Heart Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study seeks to explore the implementation characteristics (acceptability, appropriateness, feasibility, adoption, fidelity, penetration, implementation cost and sustainability) of systematic echocardiography in nursing homes and its impact on rates of heart failure flare-up and unscheduled hospitalization at 12 months among included nursing homes.
Open-label cluster randomized type 1 hybrid trial, with 2 parallel arms: nursing homes will be randomized in the interventional (echocardiography by sonographer) or non-interventional arms (usual care). In the interventional arm echocardiography will be proposed to all residents of the nursing home at baseline. Clinical management will be adapted to the result of echocardiography by the general practitioner, in accordance with the cardiologist. The main objective is to assess the impact at 12 months of the initial performance of a systematic simplified echocardiography on the rate of nursing home residents presenting with heart failure episode or cardiovascular pathology. The Primary endpoint is the number of nursing home residents presenting a heart failure episode or an unscheduled hospitalization for heart failure or other cardiovascular pathologies at 12 months.
Thirty nursing homes and 1050 residents will be included overall
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Nursing homes residents with a life-expectancy estimated > 1 year, and able to participate to the study, giving an oral consent
Exclusion Criteria :
Participants from nursing homes allocated to echocardiographic screening group will benefit of one echocardiography at inclusion.
Diagnostic Test: Implementation of echocardiography in nursing homes
Participants from nursing homes allocated to no-screening group. Participants will be followed for medical management and care as usual.
An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
Count of resident presenting a heart failure decompensation
Number of residents with heart failure flare (worsening of at least 1 NYHA class) or unplanned hospitalization for heart failure
Time frame: 12 months
Presence of a clinically significative change in medical management and care in the month following ultrasound
A binary outcome will be constructed, based on the following algorithm: clinically significative change set to "yes" if a change in ongoing drug prescription is observed, and/or a cardiologist visit is planned, and/or a geriatrist visit is planned, and/or an hospitalization for clinical work-up is set, and/or a resume of the ultrasound is sent to the GP. Otherwise (all components set to "absent"), this outcome will be set to "None".
Time frame: 12 months
Plan to share: Yes
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Oct 2028, 48 months after the start.
Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 48 months is above that.
Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jan 2028 → Oct 2028 and completion Jan 2030 → Oct 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.